STOCK TITAN

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

BioCardia (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, will host its Q3 2024 corporate update and financial results conference call on November 13, 2024, at 4:30 PM ET. The call will include management remarks followed by a Q&A session. Participants can register online or dial in (U.S.: 1-833-316-0559, International: 1-412-317-5730). A live webcast and replay will be available through November 27, 2024.

BioCardia (NASDAQ: BCDA), sviluppatore di terapie cellulari e derivate da cellule per malattie cardiovascolari e polmonari, ospiterà il suo aggiornamento aziendale del Q3 2024 e la conferenza sui risultati finanziari il 13 novembre 2024, alle 16:30 ET. La chiamata includerà osservazioni da parte della direzione seguite da una sessione di domande e risposte. I partecipanti possono registrarsi online o chiamare (USA: 1-833-316-0559, Internazionale: 1-412-317-5730). Una trasmissione web in diretta e la registrazione saranno disponibili fino al 27 novembre 2024.

BioCardia (NASDAQ: BCDA), desarrollador de terapias celulares y derivadas de células para enfermedades cardiovasculares y pulmonares, llevará a cabo su actualización corporativa del Q3 2024 y la conferencia sobre resultados financieros el 13 de noviembre de 2024, a las 4:30 PM ET. La llamada incluirá comentarios de la dirección seguidos de una sesión de preguntas y respuestas. Los participantes pueden registrarse en línea o llamar (EE.UU.: 1-833-316-0559, Internacional: 1-412-317-5730). Una transmisión web en vivo y una repetición estarán disponibles hasta el 27 de noviembre de 2024.

BioCardia (NASDAQ: BCDA)는 심혈관 및 폐 질환을 위한 세포 및 세포 유래 치료제를 개발하는 회사로, 2024년 11월 13일 오후 4시 30분 ET에 2024년 3분기 기업 업데이트 및 재무 결과 컨퍼런스 콜을 개최합니다. 이 콜은 경영진의 발언으로 시작한 후 Q&A 세션이 이어집니다. 참가자는 온라인으로 등록하거나 전화 (미국: 1-833-316-0559, 국제: 1-412-317-5730)로 접속할 수 있습니다. 실시간 웹캐스트와 재생은 2024년 11월 27일까지 이용 가능합니다.

BioCardia (NASDAQ: BCDA), développeur de thérapies cellulaires et dérivées de cellules pour les maladies cardiovasculaires et pulmonaires, organisera sa mise à jour d'entreprise et sa conférence sur les résultats financiers du T3 2024 le 13 novembre 2024 à 16h30 ET. L'appel inclura des remarques de la direction suivies d'une session de questions-réponses. Les participants peuvent s'inscrire en ligne ou composer le numéro (États-Unis : 1-833-316-0559, International : 1-412-317-5730). Un webinaire en direct et une rediffusion seront disponibles jusqu'au 27 novembre 2024.

BioCardia (NASDAQ: BCDA), ein Entwickler von Zell- und zellbasierten Therapeutika für Herz-Kreislauf- und Lungenerkrankungen, wird am 13. November 2024 um 16:30 Uhr ET seine Unternehmensaktualisierung und Finanzkonferenz für das 3. Quartal 2024 abhalten. Der Anruf umfasst Bemerkungen des Managements, gefolgt von einer Frage-und-Antwort-Runde. Teilnehmer können sich online registrieren oder anrufen (USA: 1-833-316-0559, International: 1-412-317-5730). Ein Live-Webcast und eine Wiederholung sind bis zum 27. November 2024 verfügbar.

Positive
  • None.
Negative
  • None.

SUNNYVALE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2024 by conference call on Wednesday, November 13, 2024 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session.

Participants can register for the conference by navigating to https://dpregister.com/sreg/10194429/fdf5f0e427. Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=fmwk6hNm.

A webcast replay of the call will be available approximately one hour after the end of the call through November 27, 2024 at the following link: https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will also be available through November 27, 2024 and may be accessed by calling 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada) by using access code 6220156.

About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit www.biocardia.com.


FAQ

When is BioCardia (BCDA) releasing Q3 2024 financial results?

BioCardia (BCDA) will release its Q3 2024 financial results on Wednesday, November 13, 2024, at 4:30 PM ET via a conference call.

How can I access BioCardia's (BCDA) Q3 2024 earnings call?

You can access the call by registering at dpregister.com, dialing 1-833-316-0559 (US) or 1-412-317-5730 (International), or viewing the webcast through the provided link.

Until when will BioCardia's (BCDA) Q3 2024 earnings call replay be available?

The earnings call replay will be available through November 27, 2024, via both webcast and telephone access.

BioCardia, Inc.

NASDAQ:BCDA

BCDA Rankings

BCDA Latest News

BCDA Stock Data

10.36M
3.92M
14.07%
2.22%
2.46%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SUNNYVALE